Bibliography

Bibliography

Page I

1. Adeyeye, M.C., Jain, A.C., Ghorab, M.K., Reilly, W.J. Jr. (2002) Viscoelastic evaluation of

topical creams containing microcrystalline cellulose/sodium carboxymethylcellulose as

stabilizer. AAPS Pharm SciTech, 3(2): E8.

2. Agarwal, V.A., Chiddarwar, A.P., Mahale, A.M., Wakade, R.B. (2010). Taste abatement

techniques to improve palatability of oral pharmaceuticals. International J Pharma. Research

and development; 7, 1-10.

3. Ahmed, I.S., Ayres, J.W. (2007).Bioavailability of riboflavin from a gastric retention

formulation. Int J Pharm.330, 146–54.

4. Ahuja, A., Khar, R.K., Ali, J. (1997). Mucoadhesive drug delivery systems. Drug Dev Ind

Pharm. 23, 489–515.

5. Al – Zehouri, J., Al – Madi, S., Belal, F. (2001). Arzeneim Forsch. 51, 97–103.

6. Alderman, D.A. (1978). Sustained release compositions comprising Hydroxypropyl cellulose

ethers. United States Patent No. 4,704,285.

7. Alderman, D.A., Schulz, G.J. (1989). Method of making a granular, cold water dispersible

coating composition for tablets. United States Patent No. 4,816,298.

8. Allen, L.V. (2000). Featured excipient: capsule and tablet diluents. Int J Pharm Compound 4(4),

306–310, 324–325.

9. Allen, L.V. (2000).Featured excipient: capsule and tablet diluents. Int J Pharm Compound, 4(4),

306–310, 324–325.

10. Anand, V., Kharb, V., Kataria, M., et al. (2008). Taste assessment trials for sensory analysis of

oral pharmaceutical products. Pak J Pharm Sci, 21, 438–50.

11. Augart, H., Gebhardt, U., Herrmann, W. (2000). Lactam-free amino acids. US 6,054,482, 5.

12. Augello, M., Dell, S.M., Reier, G.E., Stamato, H.J., DiMemmo, L. M. (2000). Croscarmellose

taste masking U.S. Patent, 6099865.

13. Aulton, M.E. (2002). The Science of dosage form design; Churchill living stone, 2nd edition,

414-418.

14. Bakan, J.A. (1986). Capsule part III, Microencapsulation, Theory and Practice of Industrial

Pharmacy, Third Edition, 412-429.

15. Bakan, J.A. (1986). Capsule part III, Microencapsulation, Theory and Practice of Industrial

Pharmacy, Third Edition, 412-429.

16. Banote, R.K., Koutarapu, S., Chennubhotla, K.S., Chatti, K., Kulkarni, P. (2013). Oral

gabapentin suppresses pentylenetetrazole-induced seizure-like behavior and cephalic field

potential in adult zebrafish. Epilepsy Behav. 27(1), 212-9.

17. Bar Ad, V (2010, September). "Gabapentin for the treatment of cancer-related pain

syndromes". Reviews on Recent Clinical Trials 5 (3), 174–8.

18. Becker, D., Rigassi, T., Bauer-Brandl, A. (1997). Effectiveness of binders in wet granulation:

comparison using model formulations of different tabletability. Drug Dev Ind Pharm, 23(8),

791–808.

19. Belal, F., Abdine, H., Al – Majed, A., Khalil, N.Y. (2002). J. Pharm. Biomed. Anal, 27, 253 -

260.

20. Berger, T.G., Steinhoff, M. (2011, June). "Pruritus and renal failure. "Seminars in cutaneous

medicine and surgery 30(2), 99-100.

21. Bernier, J.J., Adrian, J., Vidon, N. (1988).Les aliments dans le tube digestif, Doin, Paris.

22. Bettman, M.J., Percel, P.J., Powell, T.C. Taste masking of Pharmaceuticals. U.S. patent no.

5639475.

23. Beydoun, A., Uthman, B. M., and Sackellares, J. C. (1995). Gabapentin: Pharmacokinetics,

efficacy and safety. Clin. Neuropharmacol, 18, 469-481.

24. Beydoun, A., Uthman, B. M., Sackellares, J. C. (1995). Gabapentin: Pharmacokinetics, efficacy

and safety. Clin. Neuropharmacol., 18, 469-481.

25. Bhandari S, Review-POLYOX (Polyethylene Oxide) - Applications in Pharma Industry

Pharmainfo.net Vol. 8 Issue 3, 2010[Last assessed on 2013 Nov 20].

Bibliography

Page II

26. Blanco Fuente, H., AnguianoIgea, S., OteroEspinar, F.J., BlancoMendez, J. (1996). In-vitro

bioadhesion of carbopol hydrogels. Int J Pharm, 142,169–74.

27. Blase, C.M., Shah, M.N. (1993). Taste-Masked Pharmaceutical Suspensions for Pharmaceutical

Actives. Eur. Pat. Appl. EP0556057.

28. Borodkin S., Yonker, M.H. (1970). Journal of Pharmaceutical Sciences, 59(40), 481.

29. Borrey, D.C.R, Godderis, K.O., Engerlrelst, V.I.L., Bernard, D.R., Langlois, M.R. (2005). Clin.

Chim. Act. 354, 147–151.

30. Bottenberg, P. et al. (1991). ―Development and testing of bioadhesive Fluoride-containing Slow

release tablets for oral use‖. J. Pharm. Pharmacol, 43, 457-464.

31. Brago, D., Grepioni, F., Maini, L., Brescello, R., Cotarca, L., Duarte, M.T., Andre, V., Piedade,

M.F.M. (2008). Polymorphic gabapentin thermal behavior, reactivity and interconversion of

form in solution and solid-state. New Journal of Chemistry 32, 1788-1795.

32. Brahmankar, D.M, Jaiswal, S.B. (1995). "Biopharmaceutics and Pharmaceutics", First Edition.

PP335, 162-163,165.

33. Bravo, S., Lamas, M. C. and Salomon, C. J. (1990). In vitro studies of diclofenac sodium

controlled release from biopolymeric hydrophilic matrices. J. Pharm. Sci., 5, 213-219.

34. Browne, T.R., Holmes, G.L. (2000). In L. W. Wilkins, Handbook of Epilepsy (3rd ed., pp. 1-

20). Philadelphia.

35. Bryans, J. S. and Wustrow, D. J. (1999). 3-substituted GABA analogs with central nervous

system activity. Med. Res. Rev., 19, 149-177.

36. Bryans, J. S. and Wustrow, D. J. (1999). 3-substituted GABA analogs with central nervous

system activity. Med. Res. Rev., 19, 149-177.

37. C.M, B., & M.N, S. (1993, August 18). Patent No. Appl.EP0556057. Eur.

38. Carpay, .J ,Aldenkamp, .A, Donselaar van C . (2005). Complaints associated with the use of

antiepileptic drugs: result from a community based study. Siezure 14, 198-206.

39. Castaneda-Hernandez, G., Caille, G., du Souich, P. (1994). Influence of drug formulation on

drug concentration-effect relationships. Clin. Pharmacokinet., 26, 135-143.

40. Catania, J. (1997). Patent No. 5633006. U.S.

41. Catania, J.S., Johnson, A.D. (1997). : US5633006.

42. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research.

(2002). Estimating the safe starting dose in clinical trials for therapeutics in adult healthy

volunteers, U.S. Food and Drug Administration, Rockville, Maryland, USA.

43. Cetin, S.M., Atmaca, S. (2004). J. Chromatogr.1031, 237–242.

44. Chang, B.S., Lowenstein, D.H. (2003). Epilepsy, N.Engl.J.Med.349, 1257-1266.

45. Chang, J.H., Lee, K.C., Choi, H.J., et al. (2004). Radiographic contrast study of the upper

gastrointestinal tract of eight dogs using carboxymethylcellulose mixed with a low

concentration of barium sulphate. Vet Rec; 154(7), 201–204.

46. Charles, P., Taylor, Timothy Angelotti, Eric Fauman. (2007). Pharmacology and mechanism of

action of pregabalin: The calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic

drug discovery. Epilepsy Research, 73, 137—150.

47. Chawla, M., Raghuvanshi, R., Rampal, A. (2005). Sustained release oral tablets of gabapentin

and process for their preparation. WO 2005/020978 A1, 23.

48. Chawla, M., Raghuvanshi, R., Rampla, A. (2005). Stable sustained-release oral dosage forms of

gabapentin and process for preparation thereof. WO 2005/077332 A2, 20.

49. Cheema, D., Coomarasamy, A., El-Toukhy, T. (2007, November). "Non-hormonal therapy of

post-menopausal vasomotor symptoms: a structured evidence-based review". Archives of

Gynecology and Obstetrics 276 (5): 463–9. DOI: 10.1007/s00404-007-0390-9.

50. Cherukuri, S. R., Chau, T. K., Raman, K. P., Orama, A. M. (1991). Multiple encapsulated flavor

delivery system and method of preparation. U.S., Patent, 5004595.

51. Chilamkurti, R.N., Rhodes, C.T., Schwartz, J.B. (1982). Some studies on compression

properties of tablet matrices using a computerized instrumented press. Drug Dev Ind Pharm, 8,

63–86.

Bibliography

Page III

52. Choi, S.U., Lee, J., Choi, Y.W. (2003). Development of a directly compressible poly (ethylene

oxide) matrix for the sustained-release of dihydrocodeine bitartrate. Drug Dev. Ind. Pharm., 29,

1045-1052.

53. Chowdary, K., Kamalakara Reddy, G., Bhaskar, P. (2001). Mucoadhesive polymers – promising

excipients for controlled release. Int. J. Pharma Excip, 2, 33- 38.

54. Chowhan, Z.T. (1980). Role of binders in moisture-induced hardness increase in compressed

tablets and its effect on in vitro disintegration and dissolution. J Pharm Sci., 69, 1–4.

55. Ciavarella, B., Gupta, A., Sayeed, V.A., Khan, M.A., Faustino, P.J. (2007). J. Pharm. Biomed.

Anal, 43, 1647–1653.

56. Contreras, R.J. et al. (1995). A novel psychophysical procedure for bitter taste assessment in

rats. Chem. Senses 20, 305–312.

57. Cooper, J., Gun, C. (1986). Powder Flow and Compaction. Inc Carter SJ, Eds. Tutorial

Pharmacy. New Delhi, hidix CBS Publishers and Distributors, 211-233.

58. Corbo, M. Desai, J., Patell, M. (2003). Taste Masking Composition U.S. Patent no. 6.663.893.

59. Cotterill, J.V. et al. (2005). Masking the taste of the conditioned taste aversion agent levamisole

using an ion-exchange resin, for practical application in wildlife management. Pest Manag. Sci.

62, 120–125.

60. Cundy, K. C., Annamalai, T., Bu, L., De Vera, J., Estrela, J., Luo, W., Shirsat, P., Torneros, A.,

Yao, F., Zou, J., Barrett, R. W., and Gallop, M.A. (2004). XP13512 [(+/-)-1-([(alpha-

isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin

prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption

compared with gabapentin in rats and monkeys. J. Pharmacol. Exp. Ther., 311, 324-333.

61. Cutrignelli, A., Denora, N., Lepedota, A., Trapani, A., Laquintana, V., Latrofa, A., et al.

(2007).Comparative effects of some hydrophilic excipients on the rate of gabapentin and

baclofen lactamization in lyophilized formulations. Int J Pharm, 332(1–2), 98–106.

62. Dabbagh, M.A., Ford, J.L., Rubinstein, M.H., et al. (1999). Release of propanolol hydrochloride

from matrix tablets containing sodium carboxymethylcellulose and

hydroxypropylmethylcellulose. Pharm Dev Technol , 4(3), 313–324.

63. Dahl, T.C., Calderwood, T., Bormeth, A., et. al.(1990). Influence of physicochemical properties

of hydroxypropyl methylcellulose on naproxen release from sustained release matrix tablets. J

Control Release, 14, 1–10.

64. Danielson, D. W., Shah, S. A., U.S. Patent, 6, 270807.

65. Delonca. H., Joachim, J., Mattha, A. (1978). Influence of temperature on disintegration and

dissolution time of tablets with a cellulose component as binder. J Pharm Belg, 33, 171–178.

66. Deraguin, B.V., Smilga, V.P. (1969) London: McLaren. Adhesion: Fundamentals and Practice.

67. Desai, S.J., Singh, P., Simonelli, A.P., Higuchi, W.I. (1966). Investigation of factors influencing

release of solid drug dispersed in inert matrices, II: Quantitation of procedures. J Pharm Sci 55,

1224.

68. Deshpande, A.A., Shah, N., Rhodes, C.T., Malik, W. (1997). Development of a novel

controlled-release system for gastric retention. Pharm Res; 14, 815-19.

69. Dhawan, S., Varma, M., Sinha, V.R. (2005). High molecular weight poly (ethylene oxide)-

based drug delivery systems. Part 1: hydrogels and hydrophilic matrix systems. Pharm Technol.,

29(5), 72–74, 76–80.

70. Dichter, M.A, Brodie, M.J. (1996). New antiepileptic drugs. N.Eng.J.Med.13, 1583-1590.

71. Donnelly, R.F., McCarron, P.A., Tunney, M.M., Woolfson, A.D. (2007). Potential of

photodynamic therapy in treatment of fungal infections of the mouth, design and

characterisation of a mucoadhesive patch containing toluidine Blue O. J Photochem Photobiol

B, 86, 59–69.

72. Dorfner, K. (1972). ―Ion Exchanger Properties and Applications‖ Third Edition, Ann Arbor

Science Publisher, 2.

Bibliography

Page IV

73. Dressman, J.B., Lennerna¨s, H. (2000). Oral Drug Absorption: Prediction and Assessment,

Marcel Dekker, New York.

74. Dubernet, C. (2004). Syste`mes a` libe´ration gastrique prolonge´e, in: F. Falson-Rieg, V.

Faivre, F. Pirot (Eds.), Nouvelles formes me´dicamenteuses, E´ditions Me´dicales

Internationales, E´ ditions TEC and DOC, Cachan,119– 133.

75. Duchene, D., Touchard, F., Peppas, N.A. (1988).Pharmaceutical and medical aspects of

bioadhesive systems for drug administration. Drug Dev Ind Pharm, 14, 283–18.

76. Ezequiel Monteagudo1, Mariana Langenheim1, Claudia Salerno1, Fabia´n Buontempo1, Carlos

Bregni, and Adriana Carlucci. (2013). Pharmaceutical optimization of lipid-based dosage forms

for the improvement of taste-masking, chemical stability and solubilizing capacity of

phenobarbital. Drug Dev Ind Pharm. Early Online: 1–10.

77. Finnerup, N.B., Sindrup, S.H., Jensen, T.S. (2010, September)."The evidence for

pharmacological treatment of neuropathic pain". Pain 150 (3), 573–81.

78. Flemstrom, G., Turnberg, L.A. (1984). Gastroduodenal defence mechanisms, Clin.

Gastroenterol. 13 (2), 327–354.

79. Formaker, B.K. et al. (2004). Responses of CT single fibers were also recorded. Chem. Senses

29, 473–482.

80. Fredrickson, J.K., Kistka, J.A., Reo, J.P. (2004). : WO2004087108.

81. French, J.A., Kanner, A.M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C.L., Theodore,

W.H., Bazil, C., Stern, J., Schachter, S.C., Bergen, D., Hirtz, D., Montouris, G.D., Nespeca, M.,

Gidal, B., Marks, W.J., Turk, W.R., et.al. (2004, May). "Efficacy and tolerability of the new

antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS

Subcommittees of the American Academy of Neurology and the American Epilepsy

society". Epilepsia 45 (5), 401–9.

82. Friend, D.R., Ng, Steve, Sarabia, R.F., Weber, T.P., Geoffory, J. (2000). Taste-masked

microcapsule compositions and methods of manufacture U.S. Patent, 6139865.

83. Frieri, G., De Petris, G., Aggio, A., Santarelli, D., Ligas, E., Rosoni, R., Caprilli, R.

(1995).Gastric and duodenal juxtamucosal pH and Helicobacter pylori, Digestion 56 (2), 107–

110.

84. Fuisz, R.C. (1991). Taste-Masking of Pharmaceutical Floss with Phenol. US Patent 5,028,632.

85. Fujimori, J., Machida, Y., Nagai, T. (1994).Preparation of a magnetically-responsive tablet and

configuration of its gastric residence in beagle dogs. STP Pharma Sci, 4, 425-30.

86. Garcia, L.L, Shihabi, Z.K., Oles, K. (1995). J. Chromatogr. B. 669, 157–162.

87. Garg, R., Gupta, G.D. (2008).Progress in controlled gastroretentive delivery systems. Trop. J

Pharm Res; 7(3), 1055-66.

88. Gauger, L.J. (1984). Hydroxyethylcellulose gel as a dinoprostone vehicle. Am J Hosp Pharm,

41, 1761–1762.

89. Georage, A. (1991). Flavor masked ionizable zinc compositions for oral absorption Patent No.

US 5002970..

90. George, S., Gill, L., Braithwaite, R.A. (2000). Clin. Biochem. 37, 338–342.

91. Gerard Forrest, Graeme J. Sills, John Paul Leach, Martin J. Brodie. (1996). Determination of

gabapentin in plasma by high-performance liquid Chromatography. Journal of Chromatography

B, 681, 421-425.

92. Ghanem, A.H., Sakr, F.M., Abdel-Ghany, G. (1986). Mechanical and physical properties of

sulfamethoxazole-mannitol solid dispersion in tablet form. Acta Pharm Fenn , 95, 167–172.

93. Gidal, B. E., Radulovic, L. L., Kruger, S., Rutecki, P., Pitterle, M., and Bockbrader, H. N.

(2000). Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability.

Epilepsy Res., 40, 123-127.

94. Gidal, B.E, DeCerce, J, Bockbrder, H.N, Gonzalez, J,Kruger S. (1998). Gabapentin

Bioavailability: effect of dose and frequency on administration in adult patients with epilepsy.

Epilepsy Res. 31, 233-249.

Bibliography

Page V

95. Glibertson, T.A. et al. (2000). The molecular physiology of taste transduction. Curr. Opinion

Neurobiol. 10, 519–527.

96. Good, W.R. (1983).Transdermal nitro-controlled delivery of nitroglycerin via the transdermal

route. Drug Dev Ind Pharm, 9, 647–70.

97. Goole, J., Vanderbist, F., Aruighi, K. (2007).Development and evaluation of new multiple-

98. Gregory, S.P., Jozsa, A.J., Kaldawi, R.E. (1990). Non-Effervescent Ibuprofen Compositions.

Eur. Pat.Appl. EP0418043.

99. Grove, J., Durr, M., Quint, M.P., Plazonnet, B. (1990). The effect of vehicle viscosity on the

ocular bioavailability of -653328. Int J Pharm. 66, 23–28.

100. Gu, J.M., Robinson, J.R., Leung, S.H. (1988).Binding of acrylic polymers to mucin/epithelial

surfaces: structure– property relationships, Crit. Rev. Ther. Drug Carr. Syst. 5 (1), 21– 67.

101. Gudeman, L., Peppas, N.A. (1995). Preparation and characterisation of ph- sensitive,

interpenetrating networks of poly (vinyl alcohol) and poly (acrylic acid). J Appl Polym Sci.55,

919–28.

102. Gupta, A., Ciavarella, A.B., Sayeed, V.A., Khan, M.A., Faustino, P.J. (2008). Development and

application of a validated HPLC method for the analysis of dissolution samples of gabapentin

drug products. Pharm Biomed Anal, 46(1), 181–6.

103. Gupta H, Sharma A, Kumar S, Roy SK. (2010). E-tongue: a tool for taste evaluation. Recent Pat

Drug Deliv Formul, 4(1), 82-9.

104. Gurny, R., Meyer, J.M., Peppas, N.A. (1984) Bioadhesive intraoral release systems: Design,

testing and analysis. Biomaterials, 5, 336–40.

105. Hayward, M. (1998), U.S. Patent, 37277.

106. Higuchi, T. (1963). Mechanism of sustained action medication, Theoretical analysis of rate

release of solid drugs dispersed in solid matrices. Journal of Pharmaceutical Science, 52, 1145-

1149.

107. Hisham, E., Abdellatef, Hawa, M., Khalil. (2003). Colorimetric determination of gabapentin in

pharmaceutical formulation. Journal of Pharmaceutical and Biomedical Analysis, 31, 209-214.

108. Hitesh Jain, Rushi Pancha, Prasanna Pradhan, Hardik Patel, T. Y. Pasha. (2010, November-

December). Electronic tongue: a new taste sensor. International Journal of Pharmaceutical

Sciences Review and Research, Volume 5, Issue 2, Article-017.

109. Ho, K.Y., Gan, T.J., Habib, A.S. (2006). "Gabapentin and postoperative pain--a systematic

review of randomized controlled trials". Pain 126 (1–3), 91–101.

110. Hoffman, A. and Stepensky, D. (1999). Pharmacodynamic aspects of modes of drug

administration for optimization of drug therapy. Crit. Rev. Ther. Drug Carrier Syst., 16, 571-

639.

111. Hsu, C.H., Ke, W.T., Lin, S.Y. (2010). Progressive steps of polymorphic transformation of

gabapentin polymorphs studied by hot-stage FTIR microspectroscopy. Journal of Pharmacy and

Pharmaceutical Sciences 13(1), 67-77.

112. Hughes, L., Gehris, A. (2003). Rohm and Haas Company. Buccal dissolution of active

substances US Patent Application 20030087457 A1.

113. Hwang, J., Park, H., Park, H. (1998). Gastric retentive drug-delivery systems. Crit. Rev. Ther.

Drug Carr. Syst. 15 (3), 243– 284.

114. Iannucelli V., Coppi, G., Bernabei, M.T., Camerorni, R. (1998). Air compartment multiple-unit

system for prolonged gastric residence. Part-I-Formulation study. Int J Pharm; 174, 47-54.

115. Ibers, J.A. (2001). Gabapentin and gabapentin monohydrate. Acta Crystallographica Section C

Crystal Structure Communications 57(Pt 5), 641-643.

116. ICH GUIDELINES Q1A (R2), Guidance for industry, stability testing of new drug substance

and products (Available on: http:// http://www.ich.org).

117. Ilango, R., Kavimani, S., Mullaicharam, A.R., Jayakar, B. (1997). In vitro studies on buccal

118. International Conference on Harmonisation of Technical Requirements for Registration of

Pharmaceuticals for Human Use. (2003). Stability Testing of New Drug Substances and

Products. ICH Harmonised Tripartite Guideline Q1A(R2).

Bibliography

Page VI

119. Jain, N.K. (2001) ―Advances in Controlled and Novel Drug Delivery‖, First Edition, 290-306.

120. Jimenez-Castellanos, M.R., Zia, H., Rhodes, C.T. (1993). Mucoadhesive drug delivery

systems. Drug Dev Ind Pharm. 19, 143–94.

121. Johannessen, S.I., Ben-Menachem E. (2006). "Management of focal-onset seizures: an update

on drug treatment". Drugs 66 (13), 1701–25.

122. Jordan, N., Newton, J., Pearson, J., Allen, A. (1998).A novel method for the visualization of the

in situ mucus layer in rat and man, Clin.Sci.95 (1), 97– 106.

123. Julian, T.N., Radebaugh, G.W. (1989). : US4851226.

124. Kalviainen, R. (1997). Cognitive effects of GABAergic antiepileptic drugs, Electroencephalogr.

ClinNeurophysiol.103, 51.

125. Kamath, K.R., Park, K. (1992). Mucosal Adhesive Preparations. In: Swarbrick J, Boylan JC,

editors. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, 133.

126. Kaneko, Kanada, K., Yamada, T., Miyagi, M., Saito, M. (1997). Taste masking of

Pharmaceuticals. Chem Pharm Bull 45, 10-12.

127. Kanig, J.L. (1964). Properties of fused mannitol in compressed tablets. J Pharm Sci, 53, 188–

192.

128. Karaman, R. (2013, June). Prodrugs for masking bitter taste of antibacterial drugs—a

computational approach. J Mol Model, 19(6), 2399-412.

129. Kasturagi, Y., Sugiura, Y.C., Lee, K., Otsugi, and Kurihara. (1995). ―Selective Inhibition of

Bitter Taste of Various Drugs By Lipoprotein.‖ Pharm. Res. 12, 5, 658-662.

130. Kato, M. (1996) Japan Patent no. 8259466.

131. Katsuragi, Y. et al. (1997). Specific inhibitor for bitter taste: inhibition of from taste nerve

responses and human taste sensation to bitter stimuli. Brain. Res. Protoc. 1, 292–298.

132. Kearney, A.S., Mehta, S.C., Radebaugh, G.W. (1992). The effect of cyclodextrins on the rate of

intramolecular lactamization of gabapentin in aqueous solution. International Journal of

Pharmaceutics 78(1), 25-34.

133. Khan, A.Y., Talegaonkar, S., Iqbal, Z., Ahmed, F.J., Khar, R.K. (2006). Multiple emulsions: an

overview. Khan AY, Talegaonkar S, Iqbal Z, Ahmed FJ, Khar RK. Curr Drug Deliv, 3(4), 429-

43.

134. Kidokoro, M., Haramiishi, Y., Sagasaki, S., et al. (2002). Application of fluidized hot-melt

granulation (FHMG) for the preparation of granules for tableting; properties of granules and

tablets prepared by FHMG. Drug Dev Ind Pharm, 28(1), 67–76.

135. Kiel S.Jeffrey, Thomas Greg S, Mani Narasimhan. (2008, October 15). Gabapentin tannate in

liquid and/or semi-solid dosage forms, EP1628656.

136. Kim, E.J., Chun, M.K., Jang, J.S., Lee, I.H., Lee, K.R., Choi, H.K. (2006). Preparation of a solid

dispersion of felodipine using a solvent wetting method. Eur J Pharm Biopharm, 64(2), 200-

205.

137. Kishimoto, A., Okamoto, K. (1997). Japan Patent, 09143100.

138. Kiyoshi Toko. (2013). Biochemical Sensors: Mimicking Gustatory and Olfactory Senses CRC

Press, 146.

139. Klausner, E.A., Lavy, E., Friedman, M., Hoffman, A. (2003).Expandable gastroretentive dosage

forms. J Control Release, 90, 143-62.

140. Kolter, K., Scheiffele, S., Einig, H., Bodmeier, R. (2001). : US20010007680 A1.

141. Korsmeyer, R.W., Peppas, N.A. (1981). Effect of the morphology of hydrophilic polymeric

matrices on the diffusion and release of water soluble drugs. Journal of Membr. Science, 9, 211–

227.

142. Kovacs, B., Merényi, G. (1990). Evaluation of tack behavior of coating solutions. Drug Dev Ind

Pharm, 16(15), 2302–2323.

143. Krise, H.E., Rajendra, K.K., John, H. (2004). : US20046740341.

144. Kuchekar, B.S, Bandhan, A.C, Mahajan, H.S. (2003). "Mouth Dissolving Tablets: A Novel

Drug Delivery System". Pharma Times, 35, 7-9.

145. Kulkarni, G.M., Menjoge, A.R. (2005). : WO2005056619.

Bibliography

Page VII

146. Kulkarni A, Amol, B. Khedkar S.,et al.(2012).Development of Oral Disintegrating Tablet of

Rizatriptan Benzoate with Inhibited Bitter Taste. American-Eurasian Journal of Scientific

Research 7 (2), 47-57.

147. Kumar V, (2002). Palatable, sustained release drug granules.U.S. Patent, 6, 372, 259.

148. Kupferberg, H. (2001). Animal models used in the screening of antiepileptic drugs. Epilepsia,

42, Suppl 4, 7-12.

149. Kurusumi, T., Imamori, K., Isawa, A. (1976), Patent no. 1991,03236616. Japan.

150. Kushnir, M.M, Crosset, J, Brown, P.I., Urry, F.M.(1999). Analysis of gabapentin in serum and

plasma by solid-phase extraction and gas chromatography-mass spectrometry for therapeutic

drug monitoring. J. Anal. Toxicol, 23, 1–6.

151. Lachman, L., Lieberman, H.A., Kanig, J.L. (1987). The theory and practice of Industrial

pharmacy, Varghese Publishing House Bombay, 171-293.

152. Lachman, L., Lieberman, H.A., Kanig, J.L. (1987). The theory and practice of industrial

pharmacy; Varghese Publishing House Bombay, 293-345, 430.

153. Lakings, D.B. (1995) ―Making a successful transition from drug discovery to drug

development”. BioPharm, 8(7), 20.

154. Lamberson, R.F., Raynor, G.E. (1976). Tableting properties of microcrystalline cellulose.

Manuf Chem Aerosol News, 47(6), 55–61.

155. Lee, D.Y., Chen, C.M. (2000). Delayed pulse release hydrogel matrix tablet. United States

Patent No. 6,103,263.

156. Lehr, C.M., Poelma, F.G. (1991).An Estimate of turnover time of intestinal mucus gel layer in

the Rat in situ Loop. Int J Pharm.70, 235.

157. Lerk, C.F., Bolhuis, G.K. (1977) Interaction of lubricants and colloidal silica during mixing

with excipients II: its effect on wettability and dissolution velocity. Pharm Acta.,52(3), 39-44.

158. Leung, S.H., Robinson, J.R. (1988). The Contribution of anionic polymer structural features

related to mucoadhesion. J Control Release, 5,223–31.

159. Li, H., Hardy, R.J., Gu, X. (2008). Effect of drug solubility on polymer hydration and drug

dissolution from polyethylene oxide (PEO) matrix tablets. AAPS PharmSciTech, 9(2), 437-443.

160. Liberman, H.A., Lachman, L. (1989). ―Pharmaceutical Dosage Forms, Tablet Volume I , 11-14,

136, 198-199, 210- 212, 99-101, 159-160.

161. Lin, F.M, Lin, H.S., Kou, H.S., Wu, S.M., Chen, S.H.,Wu, H.L. (2004). Capillary

Electrophoresis Analysis of Gabapentin and Vigabatrin in Pharmaceutical Preparations as

Ofloxacin. Anal. Chim. Act. 523, 9–14.

162. Lin, S.Y., Hsu, C.H., Ke, W.T. (2010). Solid-state transformation of different gabapentin

polymorphs upon milling and co-milling. International Journal of Pharmaceutics 396(1-2), 83-

90.

163. Lindemann B. (1996). Taste perception. Physiol Rev 76, 719-766.

164. Lloret, P. (2007). Solid pharmaceutical composition of gabapentin. WO 2007/128495, 25.

165. Loscher, W., Honack, D., Taylor, C.P. (1991). Gabapentin increases aminooxyacetic acid-

induced GABA accumulation in several regions of rat brain. Neurosci Lett, 128,150–154.

166. Lulei, S. Eraden G, Nahed H. (1997). Taste masking of Pharmaceuticals. Drug Develop Ind

Pharm 23(10), 1007-1011.

167. Maccari, M., Calanchi, M., Kydonieus, A.F., (1980). 1st ed. Vol. 2. Boca, Raton, Florida: CRS

Press, Incl. Controlled Release Technologies, Methods, Theory and Applications, 113.

168. Mack, A. (2003). Examination of the evidence for off-label use of gabapentin. J. Manag. Care

Pharm.9, 1257-1266.

169. Mack, Alicia. (2003). "Examination of the evidence for off-label use of gabapentin". Journal of

Managed Care Pharmacy 9 (6), 559–68. PMID 14664664.

170. Maejima, T., Osawa, T., Nakjima, K., Kobayashi, M. (1997). Application of tumbling melt

granulation method for preparing controlled release beads coated with hydrogenated castor oil,

Chem Pharm Bull, 45(5), 904-910.

171. Magnus, L. (1999). Nonepileptic uses of gabapentin. Epilepsia 40, S66-72, discussion S73-4.

Bibliography

Page VIII

172. Manek, S. P.; Kamat, V. S., Ion Exchange Resin an Update. Indian journal of pharmaceutical

sciences, 1981; 43, 209-212.

173. Manikandan, R., Gogia, A., Roy, S., Makik, R. (2004). Gabapentin tablets and methods for their

preparation. WO 2004/032905 A1, 17.

174. Maniruzzaman, M., Boateng, J.S., Chowdhry, B.Z., Snowden, M.J., Douroumis, D. (2013, June

13). A review on the taste masking of bitter APIs: hot-melt extrusion (HME) evaluation. Drug

Dev Ind Pharm.

175. Marina Koland , Charyulu R.N., Prabhakara Prabhu. (2010, Oct-Dec). Mucoadhesive films of

Losartan Potassium for Buccal delivery: Design and Characterization. Indian J.Pharm. Educ.

Res. 44(4).

176. Martin Del Valle, E.M. (2004, May). Cyclodextrins and their uses: a review Process

Biochemistry, Volume 39, Issue 9, Pages 1033–1046.

177. Martin, A. (2001). Micromeretics, In: Martin A, ed. Physical Pharmacy. Baltimores: Lippincott

Williams and Wilkins, 423-454.

178. Mauger, J.W., Robinson, J.R., Dennis, H. (1998) US Patent no. 5,728,403.

179. McBain, J.W., Hopkins, D.G. (1925). On adhesives and adhesive action. JPhysChem; 29:188–

204.

180. McCarron, P.A., Woolfson, A.D., Donnelly, R.F., Andrews, G.P., Zawislak, A., Price, J.H.

(2004). Influence of plasticiser type and storage conditions on the properties of poly (methyl

vinyl ether-co-maleic anhydride) bioadhesive films. J Appl Polym Sci. 91, 1576–89.

181. McLean, M.J. (1995). Gabapentin: chemistry, absorption, distribution and excretion. In: R.

Levy, R. Mattson, B. Meldrum, eds. Antiepileptic Drugs, New York, Raven Press Ltd., 843–

849.

182. McLean, M.J., Gidal, B.E. (2003). Gabapentin dosing in the treatment of epilepsy. Clin. Ther.

25. 382–1406.

183. McLean, R.J., Gottlob, I. (2009). "The pharmacological treatment of nystagmus: a review".

Expert opinion on pharmacotherapy 10 (11), 1805– 16.

184. Meador, K.J. (2006). Cognitive and Memory effects of the new antiepileptic drugs. Epilepsy

Res. 68, 63-67.

185. Meilgaard, M.C. (2006). Sensory Evaluation Techniques (4th edn) CRC Press. Mendes, R.W.,

Goll, S., An, C.Q. (1978). Wet granulation: a comparison of Manni-Tab and mannitol. Drug

Cosmet Ind ,122(3): 36, 38, 40, 44, 87–88.

186. Mendes,W.R., Anaebonam, A.O., Daruwala, J.B. In, Lachman L., Liberman H.A. and Kanig

J.L. ―Theory and Practice of Industrial Pharmacy‖, Third Edition, P 346.

187. Meyer, G., M. T. (1997). Taste Masking Technologies In Oral Pharmaceuticals: Recent

Developments And Approaches. U.S. Patent, 5599556.

188. Ming, D. et al. (1998). Characterization and solubilization of bitter-responsive receptors that

couple to gustducin, Proc. Natl. Acad. Sci. U. S. A. 95, 8933–8938.

189. Ming, D. et al. (1999). Blocking taste receptor activation of gustducin inhibits gustatory

responses to bitter compounds. Proc. Natl. Acad. Sci. U.S.A., 96, 9903–9908.

190. Monograph of polyvinyl alcohol, US Pharmacopoeia USP XXII, (1990) P-5.

191. Moore, R.A. Wiffen, P.J., Derry, S., McQuay, H.J. (2011). Moore, R. Andrew. ed. "Gabapentin

for chronic neuropathic pain and fibromyalgia in adults." Cochrane database of systematic

reviews (Online) (3), CD007938.

192. Morella, A., Mario, P., In Hamilton, Heinicke, G. (2001). Taste Masked Liquid suspension. U.

S. Patent 6197348.

193. Motola, S., Agisim, G.R., Mogavero, A. (1991), Palatable Ibuprofen suspensions. U. S. Patent .

5024997.

194. Mulleners, W.M., Chronicle, E.P. (2008, June). "Anticonvulsants in migraine prophylaxis: a

Cochrane review". Cephalalgia: an international journal of headache 28 (6), 585–97.

195. Muzikova J. (2003). A study of compressibility of directly compacting forms of lactitol. Ceska

Slov Form 52(5), 241–243.

Bibliography

Page IX

196. Nafee, N.A., Boraie, N.A., Ismail, F.A., Mortada LM. (2003). Design and characterization of

mucoadhesive buccal patches containing Cetylpyridinium chloride. Acta Pharm, 53,199-212.

197. Naik, S.R., Guidotti, A., Costa, E. (1976). Central GABA receptor agonists: comparison of

muscimol and baclofen. Neuropharmacology, 15,479–84.

198. Nakano, H., Hasegawa, K. (1999) Japan Patent, 11139992.

199. Namiki, T., Tokagi, N. (1997). Taste masking of Pharmaceuticals. Japan Patent 09052850.

200. Nanda, A., Kandarapu, R., Garg, S. (2002). An update on taste masking technologies for oral

pharmaceuticals. Indian J. Pharm. Sci., 64 (1), 10–17.

201. Narasimhan, B., Peppas, N.A. (1997). Molecular analysis of drug delivery systems controlled by

dissolution of the polymer carrier. J Pharm Sci, 86,297.

202. Newton, J.L., Jordan, N., Oliver, L., Strugala, V., Pearson, J., O.F.W. James, Allen, A. (1998).

Helicobacter pylori in vivo causes structural changes in the adherent gastric mucus layer but

barrier thickness is not compromised, Gut 43 (4), 470–475.

203. Newton, J.L., Jordan, N., Pearson, J., Williams, G.V., Allen, A., James, O.F. (2000). The

adherent gastric antral and duodenal mucus gel layer thins with advancing age in subjects

infected with Helicobacter pylori, Gerontology 46 (3), 153– 157.

204. Nishikawa, M., Hayashi, H. (1992). Solid Pharmaceutical for Oral Use, JP 04,327,526.

205. Oakley, B. (1985). Taste responses of human chorda tympani nerve. Chem. Senses 10, 469–481.

206. Olgun, N., Erturk, S., Atmaca, S. (2002). Spectrofluorimetric and spectrophotometric methods

for the determination of vigabatrin in tablets.J. Pharm. Biomed. Anal., 29, 1–5.

207. Omray,A., Omray, P. (1986). Evaluation of microcrystalline cellulose as a glidant. Indian J

Pharm Sci, 48, 20–22.

208. Osugi T. (1999). Japan Patent 11139970.

209. Ozguney (Sarigullu), Ozcan, I., Ertan, G., and Guneri, T. (2007). The Preparation and

Evaluation of Sustained Release Suppositories Containing Ketoprofen and Eudragit RL 100 by

Using Factorial Design. Pharmaceutical Development and Technology, 12, 97–107.

210. Pandya, H.B, C. T. (1998).Taste masking for unplatable formulations Patent No. U.S. 5837286.

211. Panzade, P., Puranik, P. (2010). Carbopol polymer has been used in formulation & development

of taste masking of bitter active pharmaceutical ingredients. Research Journal of Pharmacy and

Technology, 3(3), 672- 675.

212. Papp et al. (1987). The ionic mechanism of the pentylenetetrazol convulsions. Acta Biol. Hung,

38 (3-4), 349.

213. Park, H., Robinson, J.R. (1985).Physicochemical properties of water soluble polymers important

to mucin/epithelium adhesion. J Control Release, 2, 47–7.

214. Park, K. (1988). Enzyme-digestible swelling as platforms for long term oral drug delivery:

synthesis and characterization. Biomaterials, 9,435.

215. Passerini, N., Perissutti, B., Monoghini, M., Voinovich, D., Albertini, B., Cavallari,

C., Rodriguez, L. (2002). Characterization of carbamazepine–Gelucire 50/13 microparticles

prepared by a spray congealing process using ultrasounds. J Pharm Sci, 91(3), 699-707.

216. Patel Satish Ambalal, Patel Natavarlal, J. (2011, Jul-Sept). Visible Spectrophotometric Methods

for Determination of Gabapentin in Pharmaceutical Tablet and Capsule Dosage Forms. Asian

Journal of Pharmacy and Life Science, Vol. 1 (3), 239-249.

217. Patell, M.K. (1990). Taste masking pharmaceutical agents. United States Patent No. 4,916,161.

218. Patsalos, P.N. (1994). Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug

pharmacokinetic interactions.Seizure, 3(3), 163–170.

219. Paulo, C., Jose Manuel, Sousa, L. (2001). Modelling and comparison of dissolution profiles.

European Journal of Pharmaceutical Science, 13, 123-133.

220. Peh, K.K., Wong, C.F., Yuen, K.H. (2000). Possible mechanism for drug retardation from

glyceryl monostearate matrix system. Drug Dev Ind Pharm, 26, 447–450.

221. Peh, K.K., Yuen, K.H. (1995). Development and in vitro evaluation of a novel multiparticulate

matrix controlled release formulation of theophylline. Drug Dev Ind Pharm, 21, 1545–1555.

Bibliography

Page X

222. Peppas, N.A., Little, M.D., Huang, Y. (2000). Bioadhesive Controlled Release Systems. In:

Wise DL, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel

Dekker, 255–69.

223. Pesachovich, M., Singer, C., Pilarski, G. (1998, July) Inventors. Teva Pharmaceutical Industries

Ltd., Israel. Teva Pharmaceuticals USA, Inc., assignee. Preparation of gabapentin. World patent

98/28255.

224. Peterson Bhoi, Dash R.K., Dalai, M.K. (2010). Formulation and in vitro evaluation of oral

floating matrix tablets of Diclofenac Sodium. International Journal of PharmTech Research,

Vol.2, No.4, 2420-2428.

225. Petroff, O.A.C., Hyder, F., Collins, T.L., Mattson, R.H., Rothman, D.L. (2000). Yale

University, New Haven, Connecticut 065208018, USA. Gabapentin raises human brain GABA

within thirty minutes. Proc. Intl. Sot. Mag. Reson. Med. 8.

226. Pharmacist’s letter / prescriber’s letter October (2008) Stability of Refrigerated and Frozen

Drugs. Vol 24, number 241001

227. Phillips, T.J., Cherry C.L., Cox S., Marshall, S.J., Rice, A.S. (2010). Pai, Nitika Pant.

ed. "Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic

review and meta-analysis of randomised controlled trials". Plos One 5 (12), e14433.

228. Prince V, Turpin KR (2008, June)."Treatment of alcohol withdrawal syndrome with

carbamazepine, gabapentin, and nitrous oxide". Am J Health Syst Pharm 65 (11), 1039–47.

229. Punit, P. Shah and Rajashree, C. Mashru. (2008). Formulation and Evaluation of Taste Masked

Oral Reconstitutable Suspension of Primaquine Phosphate. AAPS PharmSciTech, Vol. 9, No. 3.

230. Rao, M.Y. and Bader, F. (1993). ―Masking the Taste of Chloroquine by Multiple Emulsion,‖

The East. Pharm, 123, (11).

231. Raymond Long, J. (1974). Capsule and tablet administration for animals. U.S. Patent 3789845.

232. Reece, H.A., Levendis, D.C. (2008). Polymorphs of gabapentin. Acta Crystallographica Section

C Crystal Structure Communications 64(Pt 3), 105-108.

233. Reilly, W.J. (2002). Remington: The Science and Practice of Pharmacy, 20th edition, Mack

Publishing Company. 1018-1020.

234. Richter, A., Anton, S.E., Koch, P., Dennett, S.L. (2003). The impact of reducing dose frequency

on health outcomes. Clin.Ther., 25, 2307-2335.

235. Robert, L., Macdonald and Micheal, A., Rogawski. (2008). Cellular effects of Antiepileptic

Drugs. In: Jerome Engel, Timothy, A., Pedley, Jean Aicardi, eds. Epilepsy: A Comprehensive

Textbook: Volume 3. Philadelphia: Lippincott Williams and Wilkins, 1433-45.

236. Roche, E.J., Papile, S.M., Freeman, E.M. (1995). Rotogranulations and taste masking coatings

for preparation of chewable pharmaceutical tablets : EP0473431.

237. Rouge, N., Allemann, E., Gex-Fabry, M., Balant, L., Cole, E.T., Buri, P., Doelker, E.

(1998).Comparative pharmacokinetic study of a floating multiple-unit capsule, a high density

multipleunit capsule and an immediate-release tablet containing 25mg atenolol. Pharm Acta

Helbetiae, 73, 81-7.

238. Ruiz-Avila, L. et al. (2000). An In vitro assay useful to determine the potency of several bitter

compounds. Chem. Senses 25, 361–368.

239. Salman, H.H., Gamazo, C., Agueros, M., Irache, J.M. (2007). Bioadhesive capacity and

immuneadjuvant properties of thiamine-coated nanoparticles. Vaccine, 48, 8123–32.

240. Saner, R.T., Pendse, U., Moghe, A., Khedkar, S., Patil, P. (2003). Determination of gabapentin

in pharmaceutical preparations by HPTLC. Indian Drugs, 40, 547-548.

241. Santosh, U. Zate, Paresh, I. Kothawade, Mohan, N. Rathi, Mohan H. Shitole, Chetan, P.

Yewale, Vinayak, S. Gawande.(2010).Development and characterization of gastroretentive

mucoadhesive tablets of venlafaxine hydrochloride. International Journal of Drug Delivery 2,

299-303.

242. Schiffman, H.S. (2000). Sensation and Perception: An Integrated Approach, 5th ed, Ontario

Canada. John Wiley and Sons, 163-169.

Bibliography

Page XI

243. Schiffman, H.S. (2000). Sensation and Perception: An Integrated Approach, 5th ed, Ontario

Canada. John Wiley and Sons, 170-171.

244. Schiffman, S.S. et al. (2000). Effect of tricyclic antidepressants on taste responses in humans

and gerbils. Pharmacol. Biochem. Behav. 65, 599–609.

245. Scott, T.R. et al. (1999). Gustatory neural coding in the cortex of the alert cynomolgus macaque:

the quality of bitterness. J. Neurophysiol. 81, 60–71.

246. Shah, A.C., Britten, N.J., Olanoff, L.S., Badalamenti, J.N. (1989). Gel-matrix systems

exhibiting bimodal controlled release for oral delivery. J Control Release, 9, 169–175.

247. Shah, S., Qaqish, R., Patel V., Amiji, M. (1999). Evaluation of the factors influencing stomach-

specific delivery of antibacterial agents for Helicobacter pylori infection. J. Pharm. Pharmacol.

51 (6), 667– 672.

248. Shannon, H.E., Love P.L. (2004). Effects of antiepileptic drugs on working memory as assessed

by spatial alteration performance in rats. Epilepsy Behav.5, 857-865.

249. Shannon, H.E., Love P.L. (2005). Effects of antiepileptic drugs on attention as assessed by a

five choice serial reaction time task in rats. Epilepsy Behav.7, 620-628.

250. Shen, R.W. (1996) US Patent no. 5,552152.

251. Sherman, B. (2004). Solid compositions comprising gabapentin having improved stability. WO

2004/014356, 10.

252. Shrma, S., Pawar, A. (2006). Low density multiparticulate system for pulsatile release of

meloxicam. Int J Pharm, 313, 150-58.

253. Shyr-Yi Lina, Wen Shian Siowc, Hsiu-O Hoc, Ming-Thau Sheuc (2008). Development and

characterization of swellable/expandable systems for their potential application as a

gastroretentive delivery (GRD) device. Asian Journal of Pharmaceutical Sciences, 3 (1), 1-11.

254. Singla A, Chawla M, Singh A, (2000). Potential Applications of Carbomer in Oral

Mucoadhesive Controlled Drug Delivery System: A Review Drug Development and Industrial

Pharmacy, Vol. 26, No. 9, 913-924.

255. Singer, C., Pilarski, F., Pesachovich, M. (2001). Stable gabapentin containing more than 20 ppm

of chlorine ion. WO 01/97612 A1, 24.

256. Skinner, G.W., Harcum, W.W., Barnum, P.E., Guo, J.H. (1999). The evaluation of fine-particle

hydroxypropylcellulose as a roller compaction binder in pharmaceutical applications. Drug Dev

In Pharm, 25(10), 1121–1128.

257. Smart, J.D. (1991). An in vitro assessment of some mucoadhesive dosage forms. Int J

Pharm.73, 69–74.

258. Smith, D.V, Margolskee, R.F. (2001). Making sense of taste. Scientific America, 284(3), 34.

259. Smith, D.V, Margolskee, R.F. (2001). Making sense of taste. Scientific America, 284(3), 36.

260. Soderling, E., Trahan, L., Tammiala, T., Hakkinen, L. (1997). Effects of xylitol, xylitol-sorbitol,

and placebo chewing gums on the plaque of habitual xylitol consumers. Eur J Oral Sci .105(2),

170–177.

261. Sood, A., Ebbert, J.O., Schroeder, D.R., Croghan, I.T., Sood, R., Vander Weg M.W., Wong

G.Y., Hays, J.T. (2007, February). "Gabapentin for smoking cessation: a preliminary

investigation of efficacy". Nicotine & Tobacco Research 9(2), 291–8.

262. Sood, A., Ebbert, J.O., Wyatt, K.D., Croghan, I.T., Schroeder, D.R., Sood, R., Hays, J.T. (2010,

March). "Gabapentin for smoking cessation". Nicotine & Tobacco Research 12 (3), 300–4.

263. Stepensky, D., Friedman, M., Srour, W., Raz, I., and Hoffman, A. (2001). Preclinical evaluation

of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. J. Control.

Release, 71, 107-115.

264. Stevenson, C. M., Kim, J., and Fleisher, D. (1997). Colonic absorption of antiepileptic agents.

Epilepsia, 38, 63-67.

265. Stewart, B.H., Kugler, A.R., Thompson, P.R., Bockbrader, H.N. (1993). A saturable transport

mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of

proportionality between increasing dose and drug levels in plasma. Pharm. Res., 10, 276-281.

Bibliography

Page XII

266. Stone, W.E. (1972). Systemic chemical convulsants and metabolic derangements. In: Purpura

JP, Penry JK, Tower D, et al., eds. Experimental models of epilepsy: a manual for the

laboratory worker. New York: Raven Press, 407–32.

267. Stone, W.E., Javid, M.J. (1980). Aminophylline and imidazole as convulsants. Arch Int

Pharmacodyn Ther, 248,120–31.

268. Streubel, A., Siepmann, J., Bodmeier, R. (2003). Multiple unit Gastroretentive drug delivery: a

new preparation method for low density microparticles. J Microencapsul; 20, 329-47.

269. Streubel, A., Siepmann, J., Bodmeier, R. (2006). Gastroretentive drug delivery system. Expert

Opin Drug Deliv, 3(2), 217-33.

270. Strupp, M., Brandt, T. (2009, July). "Current treatment of vestibular, ocular motor disorders and

nystagmus".Therapeutic Advances in Neurological Disorders 2 (4), 223–39.

271. Stubberud, L., Arwidsson, H.G., Hjortsberg, V., Graffner, C. (1996). Water–solid interactions.

Part 3. Effect of glass transition temperature, Tg and processing on tensile strength of compacts

of lactose and lactose/polyvinyl pyrrolidone. Pharm Dev Technol, 1(2), 195–204.

272. Sugao, H., Yamazaki, S., Shizozawa, H., Yano, K. (1998). Taste masking of bitter drug powder

without loss of bioavailability by heat treatment of wax-coated microparticles.J. Pharm. Sci.,

87, 96.

273. Suhagiya, V.K., Goyani, N and Gupta, N. (2010). Taste masking by ion exchange resin and its

new applications: a review, vol. 1, issue 4.

274. Suzuki, Y., Kawasaki, Y. (1991). Syrup Composition. Eur. Pat. Appl. EP0441307.

275. Swaminathan, K., Subramania, S., Harding, R. (1997). PCT Int. Applwo, 9733621.

276. Swarbik, J. (2003). Ion Exchange Resins and Sustained Release. Encyclopedia Of

Pharmaceutical Technology Vol-8.203-217.

277. Taylor, C.P., Gee, N.S., T.Z.Su, Kocsis, J.D., Welty, D.F., Brown, J.P. (1998). A summary of

mechanistic hypotheses of gabapentin pharmacology . Epilepsy Res 29, 233-249.

278. Timmermans, J., Moes, A.J. (1993). The cutoff size for gastric emptying of dosage forms, J.

Pharm. Sci. 82 (8), 854.

279. Toko, K. (1998). Electronic sensing of taste. Electroanalysis 10, 657–669.

280. Toko, K. (2000). Taste sensor. Sens. Actuat. B. 64, 205–215.

281. Toko, K. and Habara, M. (2005). Taste sensor. Chem. Senses 30 (Suppl.1), i256–i257 26.

282. Tordoff, M.G., Bachmanov, A. A. (2003). Mouse Taste preference tests: why only two bottles?

Chem. Senses 28, 315–324.

283. Toscano, C.D, Ueda, Y., Tomita, Y.A., Vicini, S., Bosetti, F. (2008). Altered GABAergic

neurotransmission is associated with increased kainate-induced seizure in prostaglandin-

endoperoxide synthase-2 deficient mice. Brain Res Bull, 75(5), 598-609.

284. Toulis, K.A., Tzellos, T., Kouvelas, D., Goulis, D.G. (2009, February). "Gabapentin for the

treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic

review and meta-analysis". Clinical therapeutics 31 (2): 221–

35. doi:10.1016/j.clinthera.2009.02.006.PMID 19302896.

285. Uchino, H., Kanai, Y., Kim, D. K., Wempe, M. F., Chairoungdua, A., Morimoto, E., Anders, M.

W., and Endou, H. (2002). Transport of amino acid-related compounds mediated by L-type

amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol.

Pharmacol., 61, 729-737.

286. Ueda, M., Nakamura, Makata, H., Kawashima, Y.J. (1993). Microencapsulation, 10(4), 461.

287. Ueno, M., (1992) Japan Patent, 0411865.

288. Vazquez, M.J., Perez-Marcos, B., Gomez-Amoza, J.L., Martinez-Pacheco, R., Souto, C.,

Concheiro, A. (1992). Influence of technological variables on release of drugs from hydrophilic

matrices. Drug Dev Ind Pharm, 18, 1355-75.

289. Vedula, S.S., Bero, L., Scherer, R.W., Dickersin, K. (November 2009). "Outcome reporting in

industry-sponsored trials of gabapentin for off-label use." The New England Journal of

Medicine 361 (20), 1963–71.

Bibliography

Page XIII

290. Venkata Naga Jyothi, N., Muthu Prasanna1, P., Suhas Narayan Sakarkar2, k. Surya prabha1,

Seetha Ramaiah1, P. and g. Y srawan. (2010). Review: Microencapsulation techniques, factors

influencing encapsulation efficiency journal of microencapsulation, 27(3), 187–197.

291. Venkatesh, D.P., Roopa karki1, Divakar Goli1, Sajal Kumar Jha. (2013).Over view- ion

exchange resins in controlled drug Delivery system. World journal of pharmacy and

parmaceutical sciences, Volume 2, issue 6, 4764-4777.

292. Venkatesh, G.M. (2006). Taste-masked pharmaceutical compositions. U.S. 20060078614.

293. Vermeij, T.A.C., Edelborek, P.M. (2004). J. Chromatogr. B. 810, 297–303.

294. Vermeulen, J., Aldencamp A.P. (1995). Cognitive side-effects of chronic antiepileptic drug

treatment:A review of 25 years of research, Epilepsy Res.22. 65-95.

295. Vollmer, K. O., Anhut, H., Thomann, P., Wagner, F., and Jahnchen, D. (1989).

Pharmacokinetics model and absolute bioavailability of new anticonvulsant gabapentin. Adv.

Epileptol., 17, 209-211.

296. Volpe, D.A., Gupta, A., Ciavarella, A.B., Faustino, P.J., Sayeed, V.A., Khan, M.A. (2008).

Comparison of the stability of split and intact gabapentin tablets. Int J Pharm, 350(1–2), 65–9.

297. Vyas, S.P., Khar, R.K. (2002) Controlled drug delivery: concepts and advances. 1st Ed. Vallabh

prakashan, Delhi, 1-150, 167.

298. Wake, W.C. (1982) London: Applied Science Publishers. Adhesion and the Formulation of

Adhesives.

299. Wallace, J.W., Capozzi, J.T., Shangraw, R.F. (1983). Performance of pharmaceutical

filler/binders as related to methods of powder characterization. Pharm Technol, 7(9), 94–104.

300. Ward, D.R., Lathrop, L.B., Lynch, M. J. (1969). Dissolution and compatibility considerations

for the use of mannitol in solid dosage forms. J Pharm Sci 58, 1464–1467.

301. Wendel, S., Celik, M. (1997). An overview of spray-drying applications. Pharm. Technol, 124–

156.

302. Wiffen, P, Collins, S., McQuay, H., Carroll, D., Jadad, A., Moore, A. (2005). Wiffen, Philip J.

ed. "Anticonvulsant drugs for acute and chronic pain". Cochrane database of systematic reviews

(Online) (3), CD001133.

303. Wilson, H.C., Cuff, G.W. (1989). Sustained release of isomazole from matrix tablets

administered to dogs. J Pharm Sci, 78, 582–584.

304. Wolf, C.E, Saady, J.J., Poklis, A. (1996). J. Anal. Toxicol., 20, 498–501.

305. Yajima, T. et al. (2002). Method of evaluation of the bitterness of clarithromycin dry syrup.

Chem. Pharm. Bull. 50, 147–152.

306. Yajima, T., Nogata, A., Damachi, M., Umeki, N.(1996). Particle design for taste masking using

spray congelling technique, Chem. Pharm. Bull 44(1), 187.

307. Yajina,T., Ishii, K., Itai, S., Nemoto, M., Sultake, K., Tukui, N., PCT. Inl. Appl. WO 963428,

19.

308. Yande, V., Kulkarni, S., Narasimharaghavan, S., Meenakshisunderam, S. (2007). Stable liquid

formulation of antiepileptic agents. WO 2007/ 107835 A2, 9.

309. Yang, X., Robinson, J.R. (1998). Bioadhesion in Mucosal Drug Delivery. In: Okano T,

editor. Biorelated Polymers and Gels. London: Academic Press.

310. Yekta, Ozer & A. Atilla, Hincal, J. (1990) Microencapsulation, 7(3), 327.

311. Yoshinari, T., Forbes, R.T., York, P., Kawashima, Y. (2003). Improved compaction properties

of mannitol after a moisture induced polymorphic transition. Int J Pharm, 258(1–2), 121–131.

312. Yu, D., Roche, E. (2003) U.S. Patent, 6586012.

313. Zambon, E., Giovanetti, R., Cotarca, L., Pasquato, L. (2008). Mechanistic investigation on 2-

aza-spiro[4,5]decan-3-one formation from 1-(aminomethyl)cyclohexylacetic acid (gabapentin).

Tetrahedron 64(28), 6739-6743.

314. Zelalem Ayenew, Vibha Puri, Lokesh Kumar and Arvind, K., Bansal. (2009). Trends in

pharmaceutical Taste Masking Technologies: A Patent Review. Recent Patents on Drug

Delivery & Formulation, 3, 26-39.

Bibliography

Page XIV

315. Zhu, Z., Neirinck, L. (2002) High-performance liquid chromatographic method for the

determination of gabapentin in human plasma. J. Chromatogr. 779, 307–312.

316. Zixin Zhong, Desai, Salil, D.,Kaushal, Aditya, M., et al. (2011, September). The Stabilising

effect of Moisture on the Solid-State Degradation of Gabapentin. AAPS PharmSciTech, 12(3),

924-931.

317. Zotterman, Y. (1935). Action potentials in the glossopharyngeal nerve and in the chorda

tympani. Skand. Arch. Physiol. 72, 73–77.

318. Zour, E., Lodhi, S.A., Nesbitt, R.U., Silbering, S.B., Chaturvedi, P.R. (1992). Stability studies

of gabapentin in aqueous solutions. Pharmaceutical Research 9(5), 595-600.